Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buparlisib - Adlai Nortye

Drug Profile

Buparlisib - Adlai Nortye

Alternative Names: AN-2025; BKM-120; BKM120-AAA; Buparlisib hydrochloride; NVP-BKM120

Latest Information Update: 09 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis; University Hospital Tubingen
  • Developer Adlai Nortye; Array BioPharma; Dana-Farber Cancer Institute; Duke University Medical Center; Emory University; Hospices Civils de Lyon; Indiana University; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (Canada); National Cancer Institute (USA); Novartis; Novartis Oncology; Ohio State University; Paoli-Calmettes-institute; Sarah Cannon Research Institute; Stanford University; University of California at San Francisco
  • Class Amines; Antineoplastics; Morpholines; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer
  • Phase II Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Thyroid cancer
  • No development reported B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Leukaemia; Mantle-cell lymphoma; Myelofibrosis
  • Discontinued Basal cell cancer; Breast cancer; CNS cancer; Endometrial cancer; Gastrointestinal stromal tumours; Glioblastoma; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Thymoma

Most Recent Events

  • 02 Sep 2019 Emory University and Novartis terminate a phase I trial in Chronic lymphocytic leukaemia (Combination therapy, Second line therapy or greater) in USA (NCT02614508)
  • 30 Jul 2019 Array BioPharma has been acquired by Pfizer
  • 28 Jun 2019 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top